Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible

Executive Summary

FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.

You may also be interested in...

Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances

As with Purdue’s Targiniq, agency requires a post-marketing study to determine whether the new morphine/naltrexone formulation actually deters abuse.

Abuse-Deterrence Among New GDUFA Regulatory Science Priorities

FDA says it will need tools to evaluate technologies designed to deter nasal abuse in generics.

No OxyContin Comparison? Then No Priority Review For Targiniq ER

FDA rejected Purdue’s request for priority review of Targiniq ER because the NDA did not show an improvement in abuse deterrence over the sponsor’s own reformulated OxyContin, but the agency noted advantages to having both formulations available.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts